Business Wire

New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety

Jaa

Results from INPULSIS®-ON, published today in Lancet Respiratory Medicine, provide insights into the long-term safety, efficacy and tolerability of Ofev® (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF).1 These data suggest that the effect of nintedanib on slowing disease progression of IPF persists beyond four years.1 Results also indicate that the long-term efficacy of nintedanib in reducing disease progression may be sustained in patients who require dose adjustments.1

The exploratory findings of the open-label extension trial are consistent with results from the Phase III INPULSIS® trials and show that continued treatment with nintedanib, for up to 68 months, has a manageable safety and tolerability profile, with no new safety signals identified.1,2,3,4 The INPULSIS®-ON trial featured a large cohort of patients with IPF who have received nintedanib, and these data add to the growing body of evidence suggesting that nintedanib provides long-term benefits to patients with IPF.1,5

IPF is a rare, debilitating and fatal lung disease that affects approximately 3 million people worldwide.6,7,8 It causes progressive scarring of the lungs, resulting in continuous and irreversible deterioration in lung function and breathing difficulties.9 As IPF progresses, lung function gradually and irreversibly deteriorates.6

In the INPULSIS®-ON trial, involving 734 patients:

  • Descriptive efficacy assessments of lung function showed the annual rate of decline in forced vital capacity (FVC) over 192 weeks was -135.1 mL/year. This was consistent with the annual rate of FVC decline in patients treated with nintedanib in the INPULSIS® trials (-113.6 mL/year in patients treated with nintedanib).1,3 Data from clinical trials suggest that FVC decline in placebo-treated patients with IPF and mild or moderate lung function impairment at baseline is approximately 200 mL over 1 year.10
  • The annual rate of decline in FVC was consistent irrespective of age, race and FVC % predicted at the start of INPULSIS®-ON.1
  • The incidence rate of acute exacerbations in INPULSIS®-ON was similar to that in patients treated with nintedanib in the INPULSIS® trials, further supporting the effect of nintedanib on reducing the risk of acute exacerbation1,11
  • An acute exacerbation is a sudden deterioration in respiratory function, in many cases with unknown cause, which negatively impacts the disease course and often leads to death within a few months.12,13,14

The most common adverse event during INPULSIS®-ON was diarrhoea, as in the INPULSIS® and TOMORROW trials, and led to treatment discontinuation in 4.7% and 10.2% of patients who continued and initiated nintedanib during INPULSIS®-ON, respectively.1,2,3,4,10 Cardiovascular (major adverse cardiac and vascular events, e.g heart attack or stroke) and bleeding exposure-adjusted event rates collected in patients who continued or initiated nintedanib in INPULSIS®-ON were similar to those observed in placebo-treated patients in the INPULSIS® trials.1,2 These findings are also consistent with post-marketing surveillance data collected in the US during the first year following the launch of nintedanib as a treatment for IPF.15

“The results of INPULSIS®-ON add to a growing body of evidence showing that nintedanib provides long-term benefits to patients with IPF,” said Professor Bruno Crestani, lead investigator of INPULSIS®-ON, Professor of Pneumology at the Paris Diderot University School of Medicine, France and Head of the Pneumology and Rare Lung Disease Department at Bichat Hospital, France. “IPF is a chronic disease that requires long-term treatment; therefore, long-term safety and efficacy data beyond four years of treatment is important. With these positive data from INPULSIS®-ON, physicians can feel confident that their patients can benefit from nintedanib over the long term.”

Dr Susanne Stowasser, Associate Head of Medicine Respiratory at Boehringer Ingelheim said: “The INPULSIS®-ON results provide valuable insights about the long-term safety and efficacy of OFEV® in IPF and supply further evidence of its positive impact on the lives of people living with this disease.” Dr Stowasser added: “Progressive fibrosing lung diseases like IPF continue to have a devastating impact on people’s lives and our focus remains on researching and bringing to market treatments that improve the lives of these patients at need.”

~ENDS~

Please click on the link below for ‘Notes to Editors’ and ‘References’:

http://www.boehringer-ingelheim.com/press-release/inpulsis-shows-ofev-slows-progression-ipf

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.

Contact information

Boehringer Ingelheim
Corporate Communications

Media + PR
Alexander Kurz
55216 Ingelheim/Germany
Tel.: +49 (6132) 77-184531
Mobile: +49 (151) 68948378
Email: press@boehringer-ingelheim.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

IFF-LMR Naturals Leads Industry with 90 Certified Vegan Natural Extracts16.11.2018 00:15Tiedote

Regulatory News: IFF-LMR, a subsidiary of International Flavors & Fragrances Inc (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF) announced their industry-leading position of 90 natural extracts in their portfolio certified vegan by the EVE (Expertise Vegan Europe) VEGAN standards. The certified extracts include Rose EssentialTM, Rose UltimateTM, Blackcurrant Buds Absolute, Ylang Oil Complete, Vetiver Oil Haiti, Patchouli Oil Indonesia, and Geranium Heart Oil, among many others. Bertrand de Preville, General Manager, IFF-LMR said, “Our people are passionate about creating the finest ingredients and together, we are committed to delivering premium, 100% pure and natural extracts. We believe in transparency, environmental management and sustainable development.” Mr. de Preville continued, “This certification of 90 extracts is in line with IFF-LMR’s continuous dedication to our planet, people, plants and animals.” The EVE VEGAN label was selected because it is considered one of the most rigor

Rimini Street Expands Investment and Operations in Asia-Pacific15.11.2018 23:00Tiedote

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced that it has expanded its operations in the Asia-Pacific region with the launch of its new subsidiary, Rimini Street New Zealand Limited, and the opening of its new office in Auckland to address the growing demand for Rimini Street’s premium, ultra-responsive support services in New Zealand. Rimini Street’s expansion was announced at a gala event held at The Northern Club in Auckland, where clients, local IT leaders and the special guest of honor, Ambassador Scott P. Brown, the U.S. Ambassador to New Zealand, were hosted by Rimini Street’s general manager for Asia-Pacific, Andrew Powell, and Rimini Street corporate senior executives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005037/en/ Rimini Street launches subsidiary

Sartorius Stedim Biotech and Lonza Modify Relationship for Supply of Cell Culture Media15.11.2018 21:15Tiedote

Sartorius Stedim Biotech (SSB) (Paris:DIM), a leading international supplier of the biopharmaceutical industry, and Lonza announced today that they have modified their current agreement for supply of cell culture media by mutual accord. The agreement, signed in 2012, gave SSB exclusive sales and marketing rights for certain cell culture media and buffers developed and manufactured by Lonza for use in biopharmaceutical manufacturing processes. Lonza retained sales for research-based products, among others. Under agreements signed today, SSB will continue to offer current and future Lonza media and buffers on a non-exclusive basis as part of its extensive portfolio of products for cell-based development and manufacturing. Lonza Pharma & Biotech resumes sales and marketing of all its media products for both manufacturing and research. Customers of both companies will continue to be able to source media products for their specific needs. “We have a long-standing and productive partnership

Intertops Poker Launches its 20 Event Strong SOFT Series for its Recreational Player Base15.11.2018 20:46Tiedote

Intertops Poker has launched a new tournament series aimed and created for its recreational and casual player base, with impressive prizes up for grabs. The Intertops Poker SOFT Series is spread across 20 events and offers a combined prize pool of $24,850, including a $4,100 World Series of Poker Caribbean prize package. The series starts on 19th November and will conclude on 25th November. It is available to players from all countries and markets wanting to test their skills and have fun at the tables. There are a wide range of buy-ins to suit all budgets, and the tournament kicks-off with two $500 freerolls before the series gets underway proper on 20th November. Each SOFT Series event winner will receive an Intertops Poker Soft Series Champion hoodie and a seat at the table for the Champions Tournament. The highlight of the series, the Champions Tournament takes place on 25th November at 6:30pm ET and has a guaranteed World Series of Poker Caribbean prize worth $4,100. The World Ser

Telstra: Capital Planning & Delivery Named PMO of the Year15.11.2018 20:21Tiedote

Today, Project Management Institute (PMI), the world’s leading association for the project, program and portfolio management profession, announced that Telstra: Capital Planning & Delivery (Melbourne, Australia) has been awarded the 2018 PMO of the Year Award. In 2012, Telstra created the Capital Planning and Delivery (CP&D) function as a dedicated capability within the Finance and Strategy organization. Their purpose was clear – support the annual capital investment allocation, prioritization, and planning processes to better support investment programs and projects. Since that time, it has created a single enterprise wide investment gating model, created a sponsorship engagement model going from 0% of sponsors engaged at the start to 77% today, and enabled a culture of never stopping projects to one that stops non-viable efforts. With many other accomplishments, the core was a cultural transformation. Engagement of sponsors, enabling project management development opportunities and c

Acuris Risk Intelligence and FinScan® Announce Global Strategic Partnership15.11.2018 19:12Tiedote

Acuris Risk Intelligence, an independent provider of data intelligence for Anti-Money Laundering (AML), Anti-Corruption and Cyber Security; and FinScan, a global leader in AML compliance solutions, have joined forces to deliver an integrated platform for seamless and efficient watch list screening and customer due diligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005681/en/ FinScan provides advanced sanctions, Politically Exposed Persons (PEP) and adverse media screening solutions for organisations worldwide. Its intelligent matching technology drastically reduces false positives and the risk of missing true hits. By combining FinScan’s accuracy and scalability with Acuris Risk Intelligence’s specialised knowledge, the partnership enables clients to screen customers and vendors against any high-risk or sanction lists using the deployment method of their choice. Joel Lange, managing director at Acuris Risk Intel

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme